Key Calls (Tuesday): Upgrades, Downgrades & Initiations

 

 

 

 

 

Upgrade

UPGRADES:

  • Alarm.com (ALRM) upgraded to strong buy at First Analysis; PT $57
  • Arbutus Biopharma (ABUS) upgraded to buy at B Riley FBR; PT $9
  • Cracker Barrel (CBRL) upgraded to outperform at Telsey; PT $175
  • DHT Holdings (DHT) upgraded to buy at ABG; PT $8
  • Gibson Energy (GEI CN) upgraded to outperform at BMO; PT C$25
  • Government Properties (GOV) raised to equal-weight at Morgan Stanley
  • HollyFrontier (HFC) upgraded to hold at Jefferies; PT $62
  • Imperial Oil (IMO CN) upgraded to buy at Canaccord; PT C$52
  • International Flavors (IFF) upgraded to buy at Deutsche Bank; PT $154
  • Las Vegas Sands (LVS) upgraded to buy at HSBC; PT $69
  • Noodles & Co (NDLS) upgraded to buy at SunTrust; PT $15
  • Oneok Inc (OKE) upgraded to buy at Jefferies; Price Target $77
  • PNC (PNC) upgraded to strong buy at Vining Sparks; PT $155
  • Phillips 66 (PSX) upgraded to hold at Jefferies; PT $108
  • Symantec (SYMC) upgraded to market perform at Cowen; Price Target $21
  • Tapestry (TPR) upgraded to buy at Needham; PT Set to $50
  • Wabtec Corp (WAB) raised to gradually accumulate at Great Lakes Review

 

Downgrade

DOWNGRADES:

  • Amneal Pharmaceuticals (AMRX) downgraded to hold at SunTrust; PT $15
  • Antero Midstream Partners (AM) downgraded to hold at Stifel; PT $33
  • Cambium Learning (ABCD) downgraded to neutral at B Riley FBR; PT $14.50
  • Enerflex (EFX CN) cut to sector perform at Scotiabank; Price Target C$25
  • Ensign Energy Services (ESI CN) cut to sector underperform at Scotiabank
  • Ensign Energy Services (ESI CN) downgraded to in line at Evercore ISI
  • Integrated Device (IDTI) downgraded to sector weight at KeyBanc
  • Pinnacle Foods (PF) downgraded to hold at Jefferies; PT $68
  • Secure Energy Services (SES CN) cut to sector underperform at Scotiabank
  • SendGrid (SEND) downgraded to hold at Stifel; PT $37
  • Source Energy Services (SHLE CN) downgraded to neutral at CIBC; PT C$4.50
  • Southern Copper (SCCO) downgraded to hold at Santander; PT $46
  • Spero Therapeutics (SPRO) downgraded to underperform at BofAML; PT $9
  • Traverse Energy (TVL CN) downgraded to hold at Acumen; PT 15 Cents
  • Trican Well Service (TCW CN) downgraded to in line at Evercore ISI
  • Western Energy Services (WRG CN) downgraded to neutral at CIBC; PT C$1.15

 

INITIATION

INITIATIONS:

  • Abbott (ABT) rated new overweight at Barclays; PT $80
  • Avanos Medical (AVNS) rated new equal-weight at Barclays; PT $69
  • Baxter (BAX) rated new underweight at Barclays; PT $73
  • Becton Dickinson (BDX) rated new equal-weight at Barclays; PT $278
  • Booking (BKNG) rated new in line at Evercore ISI; PT $1,930
  • Boston Scientific (BSX) rated new overweight at Barclays; PT $43
  • Canopy Rivers (RIV CN) rated new buy at Eight Capital; PT C$12
  • Conmed (CNMD) rated new equal-weight at Barclays; PT $78
  • Edwards Life (EW) rated new underweight at Barclays; PT $143
  • Esperion Therapeutics (ESPR) rated new buy at BTIG; PT $82
  • Expedia (EXPE) rated new outperform at Evercore ISI; PT $140
  • Facebook (FB) rated new buy at Loop Capital; PT $210
  • Farfetch (FTCH) rated new buy at Deutsche Bank; PT $28
  • Farfetch (FTCH) rated new buy at UBS; PT $28
  • Farfetch (FTCH) rated new neutral at Goldman; PT $24
  • Farfetch (FTCH) rated new outperform at Cowen; PT $27
  • Farfetch (FTCH) rated new outperform at Wells Fargo; PT $30
  • Farfetch (FTCH) rated new overweight at JPMorgan; PT $27
  • First Finl Bankshares (FFIN) rated new neutral at Baird; PT $60
  • First Interstate Banc (FIBK) rated new outperform at Baird; PT $52
  • Genesis Healthcare (GEN) reinstated neutral at Credit Suisse; PT $1.75
  • Hill-Rom (HRC) rated new equal-weight at Barclays; PT $95
  • Independence Realty (IRT) rated new neutral at Citi; PT $10.25
  • Koppers Holdings (KOP) rated new buy at Seaport; PT $42
  • Liberty Expedia Holdings (LEXEA) rated new outperform at Evercore ISI
  • Liberty TripAdvisor (LTRPA) rated new inline at Evercore ISI; PT $12.50
  • Medtronic (MDT) rated new overweight at Barclays; PT $113
  • Perspecta (PRSP) rated new buy at Stifel; PT $35
  • Pros Holdings (PRO) rated new outperform at RBC; PT $38
  • Select Medical (SEM) rated new neutral at Credit Suisse; PT $18
  • Simmons First (SFNC) rated new outperform at Baird; PT $34
  • Sinclair Broadcast (SBGI) rated new buy at Guggenheim; PT $40
  • Snap (SNAP) rated new hold at Loop Capital; PT $7
  • Stryker (SYK) rated new overweight at Barclays; PT $198
  • Teleflex (TFX) rated new equal-weight at Barclays; PT $266
  • Tilray (TLRY) rated new buy at Benchmark; PT $200
  • TripAdvisor (TRIP) rated new in line at Evercore ISI; PT $45
  • Tuniu ADRs (TOUR) rated new outperform at Industrial Securities
  • VF Corp (VFC) rated new neutral at Wedbush; PT $94
  • West Bancorporation (WTBA) rated new outperform at Baird; PT $27
  • Y-mAbs Therapeutics (YMAB) rated new buy at BTIG; PT $35
  • Y-mAbs Therapeutics (YMAB) rated new buy at BofAML; PT $26
  • Y-mAbs Therapeutics (YMAB) rated new buy at Canaccord; PT $30
  • Y-mAbs Therapeutics (YMAB) rated new outperform at Cowen
  • Zimmer Biomet (ZBH) rated new underweight at Barclays; PT $131

 


-R.W.N II, yours in 322

Grasshopper

Banyan Capital Management, LLC (“BCM”) is a publisher, not a registered investment advisor, and nothing in BCM’s newsletter is intended, and it should not be construed, to be investment advice. BCM’s newsletter is for informational use only. Any mention in BCM’s newsletter of a particular security, index, derivative, or other instrument is neither a recommendation by BCM to buy, sell, or hold that security, index, derivative, or other instrument, nor does it constitute an opinion of BCM (or of any of its officers, employees, agents or representatives) as to the suitability of that security, index, derivative or other instrument for any particular purpose. BCM is not in the business of giving investment advice or advice regarding the suitability for any purpose of any security, index, derivative, other instrument or trading strategy and nothing in BCM’s newsletter should be so used or relied upon. BCM is not acting as your financial advisor nor in a fiduciary capacity, with regard to any securities, index, derivative or other instrument referred to in BCM’s newsletter. Also, no representation is made concerning the tax implications in any applicable jurisdiction regarding any securities, index, derivative or other instrument and BCM is not advising you in respect of the tax implications. All opinions and estimates in the newsletters are given as of the date of their publication on the BCM’s website and are subject to change and BCM does not assume any obligation to update the newsletters or to reference any such changes. BCM hereby expressly disclaims any and all representations and warranties that: (a) the content of its newsletters is correct, accurate, complete, reliable or a guaranty of future performance; (b) any of its newsletters will be available at any particular time or place, or in any particular medium; and (c) that any omission or error in any of its newsletters will be corrected. BCM shall not be liable for any errors or omissions made in its newsletters or for any inaccuracies in its assumptions. BCM specifically disclaims liability for any losses or damages (incidental, consequential or otherwise) that may arise from the newsletters and that are either used or relied upon by anyone for any reason, including without limitation, the use of the newsletters in the preparation of any financial books and records. Although from time to time BCM’s newsletter may link to or promote others’ websites or services, BCM is not responsible for and does not control those websites or services. BCM’s newsletter is published and distributed in accordance with applicable United States and foreign copyright and other laws. Without the prior written consent of BCM, no person or entity, directly or indirectly, may copy, reproduce, recompile, decompile, disassemble, reverse engineer, distribute, publish, display, perform, modify, upload to create derivative works from, transmit, or in any way exploit all or any part of BCM’s website, its newsletter, or any other material belonging to BCM.Without the prior written consent of BCM, no person or entity, directly or indirectly, may offer all or any part of BCM’s website, its newsletter, or any other material belonging to BCM for sale, nor may any person or entity, directly or indirectly, distribute all or any part of BCM’s website, its newsletter, or any other material belonging to BCM over or by means of any medium.Without the prior written consent of BCM, no person or entity, directly or indirectly, may make all or any part of BCM’s website, its newsletter, or any other material belonging to BCM, available as part of or in connection with another website, whether by hyperlink, framing on the Internet or otherwise. At any given time BCM’s principals may or may not have a financial interest in any or all of the securities and instruments discussed herein. At any given time BCM’s principals may or may not have a financial interest in any or all of the securities and instruments discussed herein.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.